References
- Agüero L., Zaldivar-Silva D., Peña L., Dias ML. Alginate microparticles as oral colon drug delivery device: A review. Carbohydrate Polymers. 2017;168:32–43. https://doi.org/10.1016/j.carbpol.2017.03.033
- Aldawsari, MF. et al. Development and Characterization of Calcium-Alginate Beads of Apigenin: In Vitro Antitumor, Antibacterial, and Antioxidant Activities. Mar. Drugs. 2021;19:467. https://doi.org/10.3390/md19080467
- European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CHMP/EWP/280/96 Rev1). 2013. (https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf)
- Gudin, J. Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain. Pain Ther. 2016;5:171–186. https://doi.org/10.1007/s40122-016-0062-1
- Jedinger, N., Schrank, S., Fischer, JM. et al. Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating. AAPS PharmSciTech. 2016;17:68–77. https://doi.org/10.1208/s12249-015-0373-2
- Maddineni S. et al. Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments. Journal of Pharmacy and Pharmacology. 2014;2:309–322. https://doi.org/10.1111/jphp.12129
- Mastropietro DJ. & Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Development and Industrial Pharmacy. 2013;39:5,611–624. DOI: 10.3109/03639045.2012.680468
- Niño-Vásquez IA. et al. Co-microencapsulation: a promising multi-approach technique for enhancement of functional properties. Bioengineered. 2022;13:3,5168–5189. DOI: 10.1080/21655979.2022.2037363
- Pasparakis G., Bouropoulos N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate–chitosan beads. International Journal of Pharmaceutics. 2006;323(1–2):34–42. https://doi.org/10.1016/j.ijpharm.2006.05.054
- Tian W., Mains J., Sleith DR. Immediate release abuse deterrent formulations (U.S. Patent No. US 2019/0117781 A1). 25 April 2019. U.S. Patent and Trademark Office.
- U.S. Department of Health and Human Services. General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products: Guidance for Industry. 2017. (https://www.fda.gov/media/96643/download)
- Vasiukhina A. et al. PLA-PCL microsphere formulation to deter abuse of prescription opioids by smoking. International Journal of Pharmaceutics. 2022;626: 122151. https://doi.org/10.1016/j.ijpharm.2022.122151.
- Walter C., Knothe, C. & Lötsch, J. Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations. Clin Pharmacokinet 2016;55:751–767. https://doi.org/10.1007/s40262-015-0362-3